ABSTRACT
BACKGROUND: Consent and wound care (WC) videos are used for education in Mohs micrographic surgery (MMS). Postoperative text messaging is poorly studied. OBJECTIVE: Develop and evaluate perioperative resources for MMS patients-video modules (DermPatientEd.com) and postoperative text messaging (DermTexts.com). MATERIALS AND METHODS: A study was conducted on 90 MMS patients. Patients were randomized 1:1:1:1 to videos with text messages, videos-only, text messages-only, or control. Primary outcomes included preoperative anxiety and knowledge of MMS and postoperative care. The secondary outcome included helpfulness/preference of interventions. RESULTS: Patients experienced a 19% reduction in anxiety as measured by a visual analog scale after the MMS video (p = .00062). There was no difference in knowledge after the WC video (p = .21498). Patients were more likely to report the WC video "very helpful" when compared with the pamphlet in understanding postoperative WC (p = .0016). Patients in text messaging groups were not more likely to report the service as "very helpful" when compared with the pamphlet (p = .3566), but preferred to receive WC instructions by text message for future visits (p = .0001). CONCLUSION: These resources proved helpful and effective in reducing preoperative anxiety. Patients prefer text message-based WC instructions over pamphlets after experiencing the service, but do not find them more helpful.
Subject(s)
Computer-Assisted Instruction , Mobile Applications , Mohs Surgery/education , Patient Education as Topic/methods , Postoperative Care/education , Text Messaging , Adolescent , Adult , Aged , Anxiety/etiology , Anxiety/prevention & control , Female , Humans , Male , Middle Aged , Mohs Surgery/psychology , Patient Preference , Patient Satisfaction , Pilot Projects , Skin Neoplasms/psychology , Skin Neoplasms/surgery , Young AdultABSTRACT
Herpes zoster (HZ), or shingles, is commonly seen in older adults but does occur in children. Routine administration of the varicella vaccine started in 1995 in the United States; since then, the incidence of varicella and HZ has declined. We report a case of HZ in an otherwise healthy 19-month-old boy who had been vaccinated at 13 months of age and recovered fully after acyclovir treatment. We review previously reported cases of HZ in healthy vaccinated children.
Subject(s)
Acyclovir/administration & dosage , Antiviral Agents/administration & dosage , Chickenpox Vaccine/adverse effects , Herpes Zoster/etiology , Chickenpox/prevention & control , Chickenpox Vaccine/administration & dosage , Humans , Infant , MaleABSTRACT
BACKGROUND: Linear morphea can lead to significant morbidity and functional disability in young patients. Methotrexate (MTX), with or without a short initiation with prednisone therapy, has been used and documented as a well-tolerated, effective treatment regimen. PURPOSE: To evaluate the long-term efficacy of MTX therapy in patients with linear morphea. METHODS: A retrospective chart review was performed for pediatric and young adult patients with linear morphea and evaluated in the Dermatology Clinic at Wake Forest University School of Medicine treated with MTX. RESULTS: Seventeen patients met inclusion criteria and were followed for an average of 6.6 years. All patients improved with MTX therapy, with an average of 2.1 months to disease inactivity, and 19.6 months to discontinuation of MTX. Seven patients (41%) required a second course of MTX, following an average remission of 21 months. One patient (6%) required a third course, following 6.9 years of remission. LIMITATIONS: Retrospective chart review with a small patient sample size, and several patients were lost to follow-up. CONCLUSIONS: MTX is effective for achieving disease inactivity in pediatric and young adult patients with linear morphea. MTX is also effective in achieving disease remission off of therapy. However, many patients eventually required more than one course of MTX.
Subject(s)
Dermatologic Agents/therapeutic use , Methotrexate/therapeutic use , Scleroderma, Localized/drug therapy , Adolescent , Adult , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Prednisone/therapeutic use , Remission Induction , Retrospective Studies , Time Factors , Young AdultABSTRACT
BACKGROUND: Atopic dermatitis (AD) is a prevalent skin disorder with significant cost of treatment. Several prescription device moisturizers have been approved by the FDA to treat AD but are significantly more expensive than well-crafted over-the-counter (OTC) moisturizers. No studies have been performed to compare both the clinical efficacy and cost-efficacy of these prescription devices to OTC moisturizers. PURPOSE: The purpose of this study is to compare the clinical efficacy and cost-efficacy of a glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®), a ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®) and an OTC petroleum-based skin protectant moisturizer (OTC-Pet, Aquaphor Healing Ointment®) as monotherapy for mild-to-moderate AD in children. METHODS: Thirty-nine patients, age 2-17 years, with mild-to-moderate AD were randomized 1:1:1 to receive one of three treatments-BRC-Gly, BRC-Cer or OTC-Pet-with instructions to apply the treatment three times daily for three weeks. Disease severity and improvement was assessed at baseline and on days 7 and 21. RESULTS: No statistically significant difference for any efficacy assessment was found between the three groups at each time point. The OTC-Pet was found to be at least 47 times more cost-effective than BRC-Gly or BRC-Cer. LIMITATIONS: The relatively small sample size of 39 subjects was not sufficient to establish OTC-Pet as superior treatment in AD. CONCLUSIONS: OTC-Pet is as effective in treating mild-to-moderate AD as both BRC-Gly and BRC-Cer and is at least 47 times more cost-effective. NAME OF REGISTRY: II-AF-ATD-Aquaphor, Comparing the Efficacy and Cost-Effectiveness of Aquaphor to Atopiclair and EpiCeram in Children with Mild to Moderate Atopic Dermatitis. REGISTRATION IDENTIFIER: NCT01093469.
